These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25135423)

  • 1. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
    Farid N; Almeida-Freitas DB; White NS; McDonald CR; Kuperman JM; Almutairi AA; Muller KA; VandenBerg SR; Kesari S; Dale AM
    J Neurooncol; 2014 Dec; 120(3):539-46. PubMed ID: 25135423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
    Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
    J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between radiation dose and bevacizumab-related imaging abnormality in patients with brain tumors: A voxel-wise normal tissue complication probability (NTCP) analysis.
    Salans M; Houri J; Karunamuni R; Hopper A; Delfanti R; Seibert TM; Bahrami N; Sharifzadeh Y; McDonald C; Dale A; Moiseenko V; Farid N; Hattangadi-Gluth JA
    PLoS One; 2023; 18(2):e0279812. PubMed ID: 36800342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
    Hesselink JR; Barkovich MJ; Seibert TM; Farid N; Muller KA; Murphy KT; Kesari S
    CNS Oncol; 2014; 3(5):329-35. PubMed ID: 25363005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
    Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
    AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors.
    Rollin N; Guyotat J; Streichenberger N; Honnorat J; Tran Minh VA; Cotton F
    Neuroradiology; 2006 Mar; 48(3):150-9. PubMed ID: 16470375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
    Schmainda KM; Prah M; Connelly J; Rand SD; Hoffman RG; Mueller W; Malkin MG
    Neuro Oncol; 2014 Jun; 16(6):880-8. PubMed ID: 24431219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging.
    Arvinda HR; Kesavadas C; Sarma PS; Thomas B; Radhakrishnan VV; Gupta AK; Kapilamoorthy TR; Nair S
    J Neurooncol; 2009 Aug; 94(1):87-96. PubMed ID: 19229590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.
    Mong S; Ellingson BM; Nghiemphu PL; Kim HJ; Mirsadraei L; Lai A; Yong W; Zaw TM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Oct; 33(9):1763-70. PubMed ID: 22538078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?
    Horváth A; Perlaki G; Tóth A; Orsi G; Nagy S; Dóczi T; Horváth Z; Bogner P
    J Neurooncol; 2016 Mar; 127(1):83-90. PubMed ID: 26614516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
    Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
    Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.
    Matsusue E; Fink JR; Rockhill JK; Ogawa T; Maravilla KR
    Neuroradiology; 2010 Apr; 52(4):297-306. PubMed ID: 19834699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
    Gahramanov S; Muldoon LL; Li X; Neuwelt EA
    Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage signal intensity recovery: A step ahead of rCBV in DSC MR perfusion imaging for the differentiation of common neoplasms of brain.
    Surendra KL; Patwari S; Agrawal S; Chadaga H; Nagadi A
    Indian J Cancer; 2020; 57(1):36-43. PubMed ID: 31898591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.
    Boxerman JL; Schmainda KM; Weisskoff RM
    AJNR Am J Neuroradiol; 2006 Apr; 27(4):859-67. PubMed ID: 16611779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.